Collegium Pharmaceutical (NASDAQ:COLL) received a $23.00 price target from equities researchers at Piper Jaffray Companies in a research note issued on Thursday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ target price would indicate a potential upside of 32.95% from the company’s current price.

Several other analysts also recently commented on the stock. HC Wainwright initiated coverage on shares of Collegium Pharmaceutical in a report on Monday, September 11th. They issued a “buy” rating and a $21.00 price objective on the stock. Jefferies Group reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Collegium Pharmaceutical in a report on Thursday, September 21st. Needham & Company LLC reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 6th. Finally, Zacks Investment Research raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a report on Monday, November 13th. Two research analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. Collegium Pharmaceutical currently has an average rating of “Buy” and an average target price of $23.33.

Shares of Collegium Pharmaceutical (NASDAQ COLL) opened at $17.30 on Thursday. Collegium Pharmaceutical has a twelve month low of $7.37 and a twelve month high of $20.92.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.28. The business had revenue of $11.95 million for the quarter, compared to the consensus estimate of $5.31 million. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The business’s revenue for the quarter was up 2814.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.13) EPS. sell-side analysts expect that Collegium Pharmaceutical will post -2.52 earnings per share for the current fiscal year.

In related news, major shareholder Longitude Capital Partners, Ll sold 1,000,000 shares of the business’s stock in a transaction on Friday, December 8th. The shares were sold at an average price of $17.34, for a total value of $17,340,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael Thomas Heffernan sold 50,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $15.53, for a total transaction of $776,500.00. Following the completion of the transaction, the chief executive officer now owns 558,987 shares of the company’s stock, valued at $8,681,068.11. The disclosure for this sale can be found here. Insiders sold a total of 1,058,630 shares of company stock worth $18,264,360 over the last ninety days. Insiders own 25.76% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Credit Suisse AG lifted its stake in shares of Collegium Pharmaceutical by 9.4% in the 1st quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock valued at $137,000 after purchasing an additional 1,173 shares during the period. Nationwide Fund Advisors lifted its stake in shares of Collegium Pharmaceutical by 27.8% in the 2nd quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock valued at $161,000 after purchasing an additional 2,802 shares during the period. Royal Bank of Canada lifted its stake in shares of Collegium Pharmaceutical by 12.7% in the 2nd quarter. Royal Bank of Canada now owns 29,139 shares of the specialty pharmaceutical company’s stock valued at $365,000 after purchasing an additional 3,285 shares during the period. Geode Capital Management LLC lifted its stake in shares of Collegium Pharmaceutical by 3.4% in the 1st quarter. Geode Capital Management LLC now owns 146,568 shares of the specialty pharmaceutical company’s stock valued at $1,474,000 after purchasing an additional 4,866 shares during the period. Finally, Wells Fargo & Company MN lifted its stake in shares of Collegium Pharmaceutical by 12.8% in the 3rd quarter. Wells Fargo & Company MN now owns 45,254 shares of the specialty pharmaceutical company’s stock valued at $475,000 after purchasing an additional 5,136 shares during the period. Hedge funds and other institutional investors own 79.98% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/12/15/collegium-pharmaceutical-coll-given-a-23-00-price-target-by-piper-jaffray-companies-analysts.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Stock Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related stocks with our FREE daily email newsletter.